Diffuse large B cell lymphoma
Conditions
Interventions
observation group:The enrolled patients were treated with polatuzumab vedotin (Pola) combined with rituximab (R) and dexamethasone: Pola 1.8mg/kg IV day1, R 375mg/m2 IV day1, dexamethasone 15mgQd day1
Sponsors
Beijing hospital
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) CD20-positive diffuse large B-cell lymphoma was diagnosed according to the 5th edition of the World Health Organization (WHO) classification of hematopoietic and lymphocytic neoplasms; 2) no previous lymphoma-related treatment; 3) age =80 years old or age=65 years old and FIL-CGA score for fragile groups; 4) presence of at least one measurable lesion; 5) the expected survival time is more than 3 months; 6) Patients voluntarily agreed to participate in the study and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1) severe uncontrolled infection or autoimmune disease; 2) the baseline liver and kidney dysfunction (alanine aminotransferase and aspartate aminotransferase levels more than 2 times the upper limit of normal (ULN), alkaline phosphatase (or bilirubin level more than 1.5 x ULN, creatinine level more than 1.5 x ULN); 3) active hepatitis B or C (HBsAg positive and/or HBcAb positive and HBV DNA = 104 copies or = 4000IU/ml; HCV antibody positive) or human immunodeficiency virus (HIV) antibody positive; 4) known allergy to the test drug; 5) those who were considered unsuitable for enrollment by the researchers; 6) in patients with poor compliance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival rate;progression-free rate; | — |
Countries
China
Contacts
Public ContactHui Liu
Beijing hospital
Outcome results
None listed